Medigene AG: Medigene's Drug Veregen® Launched in Canada

           Medigene AG: Medigene's Drug Veregen® Launched in Canada

Medigene AG / Medigene's Drug Veregen® Launched in Canada . Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.

Press release

Martinsried/Munich,  July  17,  2014.  Medigene  AG  (MDG1,  Frankfurt,  Prime 
Standard) announces the launch of its drug Veregen^® (Sinecatechins  Ointment, 
10%) for  the treatment  of  genital warts  in  Canada through  the  marketing 
partner Paladin Labs Inc. (who acquired  Triton Pharma). Within the scope  of 
the license agreement, Medigene receives  sales milestone payments as well  as 
royalties on Veregen^® sales.

Up to  now,  Veregen^® is  available  in the  USA,  in 15  European  countries 
(Germany, Austria,  Switzerland,  Spain,  Serbia,  the  Netherlands,  Belgium, 
Norway, Sweden,  Denmark,  Finland,  Czech Republic,  Slovakia,  Hungary,  and 
Poland), and in Taiwan. The drug has  obtained market approval in a number  of 
additional countries.  Several  marketing  partnership  agreements  have  been 
concluded in Europe, Asia, and America.

About Veregen^®:  Veregen^®,  a  topical treatment  for  external  genital  or 
perianal warts, contains  a concentrate  of catechins with  a complex  defined 
composition extracted from green tea leaves. Sinecatechins 10% & 15%  Ointment 
(Veregen^®)  has  been  included  in  the  2012  European  Guideline  for  the 
Management  of  Anogenital  Warts.  In  addition,  in  its  current  Sexually 
Transmitted Diseases Treatment Guidelines, the US Centers for Disease  Control 
and Prevention includes Sinecatechins 15%  Ointment (Veregen^®) as a  possible 
option for treating genital warts.

About Paladin Labs Inc.: Paladin Labs Inc., headquartered in Montreal, Canada,
is a specialty  pharmaceutical company  focused on  acquiring or  in-licensing 
innovative pharmaceutical products for  Canadian and select emerging  markets. 
Paladin has a  focused marketing  and sales  organization that  has helped  it 
evolve into  one  of  Canada's  leading  specialty  pharmaceutical  companies. 
Paladin is an operating company of Endo International plc, a global  specialty 
healthcare  company  focused  on  improving  patients'  lives  while  creating 
shareholder value. Learn more at www.endo.com.

Medigene  AG  is   a  publicly  listed   (Frankfurt:  MDG1,  prime   standard) 
biotechnology company  headquartered  in  Martinsried  near  Munich,  Germany. 
Medigene  concentrates   on   the   development   of   personalized   T   cell 
immunotherapies with  focus on  haematological malignancies.  Medigene is  the 
first German biotech company to have  revenues from a marketed product,  which 
is distributed by commercial partners. Medigene has various drug candidates in
clinical  development  and  it  is  developing  highly  innovative   treatment 
platforms. For more information, please visit www.medigene.de.

This  press  release  contains  forward-looking  statements  representing  the 
opinion of  Medigene  as of  the  date of  this  release. The  actual  results 
achieved  by  Medigene  may  differ  significantly  from  the  forward-looking 
statements made  herein.  Medigene  is  not  bound  to  update  any  of  these 
forward-looking statements. Medigene^® and Veregen^® are registered trademarks
of Medigene AG. Polyphenon E^® is a trademark of Mitsui Norin Co., Ltd.  These 
trademarks may be owned or licensed in select locations only.

Contact
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe  from  the  press  release distribution  list,  please  go  to: 
www.medigene.de/unsubscribe

Press release as PDF

------------------------------------------------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
HUG#1827750

--- End of Message ---

Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
 
Press spacebar to pause and continue. Press esc to stop.